Ohta Y, Tomita Y, Oda M, et al.: Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg 1999, 68:1034–1038. ArticlePubMedCAS Google Scholar
Linderholm B, Grankvist K, Wilking N, et al.: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000, 18:1423–1431. This clinical study demonstrates the importance of VEGF as an independent prognostic marker for node-positive breast cancer. PubMedCAS Google Scholar
Imoto H, Osaki T, Taga S, et al.: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998, 115:1007–10014. ArticlePubMedCAS Google Scholar
Jacobsen J, Rasmuson T, Grankvist K, et al.: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000, 163:343–347. ArticlePubMedCAS Google Scholar
Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999, 5:1359–1364. Concise review of the multiple roles for manipulation of the VEGF pathway in experimental therapeutics for many human diseases. ArticlePubMedCAS Google Scholar
Antiangiogenesis Information [database online]. Bethesda, MD: National Cancer Institute; 2000. Available at http:// cancertrials.nci.nih.gov/news/angio/index.htm Updated summary of the ongoing clinical trials for angiogenesis inhibitors for cancer therapy, accessible via the Internet.
Beckner ME: Factors promoting tumor angiogenesis. Cancer Invest 1999, 17:594–623. Excellent summary of the multiple factors interacting to influence the process of angiogenesis. ArticlePubMedCAS Google Scholar
Pavco PA, Bouhana KS, Gallegos AM, et al.: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000, 6:2094–2103. PubMedCAS Google Scholar
Senger DR, Galli SJ, Dvorak AM, et al.: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983–985. ArticlePubMedCAS Google Scholar
Leung DW, Cachianes G, Kuang WJ, et al.: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306–1309. ArticlePubMedCAS Google Scholar
Shibuya M: Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995, 67:281–316. ArticlePubMedCAS Google Scholar
Ellis LM, Takahashi Y, Liu W, Shaeen RM: Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000, 5(suppl 1):11–15. ArticlePubMedCAS Google Scholar
Benjamin LE, Golijanin D, Itin A, et al.: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159–165. PubMedCAS Google Scholar
Jakeman LB, Winer J, Bennett GL, et al.: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992, 89:244–253. PubMedCAS Google Scholar
Neufeld G, Cohen T, Gebrinovtch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999, 13:9–22. PubMedCAS Google Scholar
Gabrilovich D, Ishida T, Oyama T, et al.: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150–4166. This article highlights the potential importance of VEGF as an immunosuppressive agent in cancer biology. PubMedCAS Google Scholar
Speirs V, Atkin SL: Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer 1999, 80:898–903. ArticlePubMedCAS Google Scholar
Decaussin M, Sartelet H, Robert C, et al.: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999, 188:369–377. ArticlePubMedCAS Google Scholar
Liu B, Earl HM, Baban D, et al.: Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995, 217:721–727. ArticlePubMedCAS Google Scholar
Shalaby F, Ho J, Standford WL, et al.: A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 1997, 89:981–990. ArticlePubMedCAS Google Scholar
Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66–70. ArticlePubMedCAS Google Scholar
Barleon B, Siemeister G, Martiny-Baron G, et al.: Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 1997, 57:5421–5425. PubMedCAS Google Scholar
Kim KJ, Winer J, Armanini M, et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841–844. ArticlePubMedCAS Google Scholar
Zhang HT, Craft P, Scott PA, et al.: Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995, 87:213–219. ArticlePubMedCAS Google Scholar
Zaug AJ, Been MD, Cech TR: The Tetrahymena ribzyme acts like an RNA restriction endonuclease. Nature 1986, 324:429–433. ArticlePubMedCAS Google Scholar
Baer M, Altman S: A catalytic RNA and its gene from Salmonella typhimurium. Science 1985, 228:998–1002. Article Google Scholar
Usman U, Stinchcomb D: Design, synthesis and function of therapeutic hammerhead ribozymes. In Nucleic Acids and Molecular Biology. Edited by Eckstein R, Lilley D. Berlin: Springer-Verlag; 1996:243–264. Google Scholar
Usman N, Beigelman L, McSwiggen JA: Hammerhead ribozyme engineering. Curr Opin Struct Biol 1996, 6:527–533. ArticlePubMedCAS Google Scholar
Fell PL, Hudson A, Reynolds MA, et al.: Cellular uptake properties of a 2′-amino/2′-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. Antisense Nucleic Acid Drug Dev 1997, 7:319–326. PubMedCAS Google Scholar
Parry TJ, Cushman C, Gallegos AM, et al.: Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 1999, 27:2569–2577. ArticlePubMedCAS Google Scholar
Sandberg JA, Bouhana KS, Gallegos AM, et al.: Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. Antisense Nucleic Acid Drug Dev 1999, 9:271–277. PubMedCAS Google Scholar
Parker VP, Sandberg JA, Smith J, et al.: Phase I and pharmacokinetic studies of Angiozyme, a synthetic ribozyme targeting the VEGF receptor Flt-1 [abstract]. Proc ASCO 2000, 19:703a. Google Scholar